Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
|Videos|October 21, 2017
Diagnosing G3 NETs and NECs
Author(s)Jennifer Eads, MD
Jennifer Eads, MD, assistant professor of medicine, senior clinical instructor of medicine, University Hospitals Cleveland Medical Center, discusses the difficulties in diagnosing G3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), and the varying treatment approaches for these subsets of patients.
Advertisement
Advertisement
Related to this article
The phase 2/3 AHEAD-MERIT trial will continue to evaluate patients with HPV-positive head and neck squamous cell carcinoma for its second primary end point of overall survival.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5